AstraZeneca’s Imfinzi Shows Significant Improvement in Survival Rates for Limited-Stage Small Cell Lung Cancer Patients A recent Phase III trial, ADRIATIC, revealed promising outcomes for AstraZeneca’s Imfinzi (durvalumab) in treating…
Merck, known as MSD outside of the United States and Canada, has announced the commencement of a Phase 3 clinical trial to evaluate MK-1084, an investigational oral selective KRAS G12C…
Bristol Myers Squibb (NYSE: BMY) has unveiled its 2023 Environmental, Social, and Governance (ESG) Report, spotlighting significant progress, a refined strategy, and ambitious goals in its ESG initiatives. Rooted in…
Bristol Myers Squibb (NYSE: BMY) has disclosed that the European Commission (EC) has broadened the approval of Reblozyl® (luspatercept) to encompass the initial treatment of adult patients grappling with transfusion-dependent…
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been officially accepted in the United States. This application targets the treatment of adult patients grappling with…
WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), trading as WuXi Bio (2269.HK), proudly announces its sweeping victory at the 2024 CDMO Leadership Awards. The company…
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, referred to as “Astellas”) has received notification from the U.S. Food and Drug Administration (FDA) regarding the acceptance of the…
Eisai Co., Ltd. (based in Tokyo, CEO: Haruo Naito) and Biogen Inc. (headquartered in Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) have jointly announced the submission of a Supplemental Biologics License…
The recent occurrences of avian influenza outbreaks, observed last year, underscore the sobering reality of zoonotic influenza. These events emphasize that individuals of all ages are susceptible, regardless of comorbidities,…
Last year witnessed several outbreaks that underscore the reality of zoonotic influenza, revealing vulnerabilities across all age groups and highlighting the risks for individuals both with and without comorbidities. These…
A global immunology company dedicated to enhancing the lives of individuals grappling with severe autoimmune conditions has unveiled its intention to propel the development of efgartigimod into Phase 3 for…
The CVS Health® (NYSE: CVS) today announced more than $3 million in new grants to support organizations in Phoenix working to increase equitable access to health care, address social determinants of…